Adverse effect · Amycretin

How common is GI side effects with Amycretin?

C
Grade C — weak human evidence1 phase 1b/2a RCT · effect size: moderate · adverse
Short answerWeak human evidence. 1 phase 1b/2a RCT: enough to be interesting, not enough to count on. Where an effect is seen it is a moderate effect. Gastrointestinal events were frequent, as with every drug in this class, and mostly resolved.

What the studies show

Gastrointestinal events were frequent, as with every drug in this class, and mostly resolved.

“The most common treatment-emergent adverse events were gastrointestinal, and the majority were mild to moderate in severity and resolved by the end of the study.”

Verbatim, from the abstractDahl K, et al. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. Lancet, 2025;406:149–162

A few small or poorly-controlled human studies. Enough to be interesting; not enough to count on. Most of what gets called “clinically proven” online lives here.

  1. 1

In context

Amycretin is a single molecule that activates both the GLP-1 and the amylin receptor, combining the two mechanisms that CagriSema delivers as two drugs. Its international name is now zenagamtide. In the first published trial — a phase 1b/2a study in 125 people — the highest dose produced 24.3% weight loss at 36 weeks: the largest figure reported for any weight-loss drug at this stage, from a small, early trial in which many participants withdrew. Two phase 2 trials in type 2 diabetes, published in The Lancet in 2026, add a dose-dependent HbA1c reduction of up to 1.7 points; the weight-loss figure has not yet been repeated in a larger trial.

Amycretin is investigational (early phase). Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Amycretin proven to cause GI side effects?
No. The human evidence is weak (1 phase 1b/2a RCT); LYO grades it C.
What studies are behind the grade?
Gastrointestinal events were frequent, as with every drug in this class, and mostly resolved.
Is Amycretin approved for this?
No. Amycretin is investigational (early phase); it is not an approved medicine for any indication in the jurisdictions LYO covers.

Other outcomes for Amycretin

Written and maintained by LYO Research — how pages are written and checked. Reviewed 23 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →